Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death
mBio · 2023
DOI: 10.1128/mbio.03459-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2023. Verfasst von Philip T Lange und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoma, Lymphoma, B-Cell. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
EBV is a ubiquitous pathogen responsible for significant global lymphoma burden, including Hodgkin lymphoma, numerous non-Hodgkin B, T, and NK cell lymphomas, and lymphoproliferative disorders. EBV is also associated with epithelial cancers and autoimmune diseases, such as multiple sclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Blossom Damania
Förderung
- NCI NIH HHS
- NIDCR NIH HHS
- NIAID NIH HHS
- HHS | National Institutes of Health
- Lymphoma Research Foundation
Zitieren
APA
Lange, P. T., & Damania, B. (2023). Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death. mBio. https://doi.org/10.1128/mbio.03459-22
Vancouver
Lange PT, Damania B. Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death. mBio. 2023. doi:10.1128/mbio.03459-22
BibTeX
@article{Lange2023,
author = {Lange, Philip T and Damania, Blossom},
title = {Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.03459-22}
}
EUVIMED